Patients With Necrotizing Skin and Soft Tissue Infections Managed Within the SURFAST Care Pathway.

Patients With Necrotizing Skin and Soft Tissue Infections Managed Within the Great Paris Area SURFAST Care Pathway: a Prospective, Multicenter Cohort Study.

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07417982

Acronym

SURFAST

Enrollment

1000

Registered

2026-02-18

Start date

2026-03-01

Completion date

2036-06-01

Last updated

2026-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Necrotizing Soft-tissue Infections

Keywords

Necrotizing soft-tissue infections, necrotizing fasciitis, Skin and soft tissue necrotizing infections, SURFAST

Brief summary

Necrotising soft-tissue infections (NSTIs) are rare and life-threatening skin and soft tissue infections requiring urgent combined medical and surgical management in specialist centres. At Assistance Publique-Hôpitaux de Paris, a multidisciplinary reference network called the SURFAST consortium has been established. This network includes experts in the management of NSTIs, such as intensivists, dermatologists, infectious disease physicians, paediatricians, surgeons, and microbiologists. The consortium manages all NSTI cases referred from the greater Paris area, a large region of France with a population exceeding 12 million. The SURFAST network comprises care pathways enabling the management of adult and paediatric patients with abdomino-perineal, limb, and cervico-facial NSTIs. All patients managed within this care pathway are included in a prospective, multicentre cohort study. This study examines factors associated with mortality at day 90, long-term sequelae, quality of life, and indicators of the quality of care.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

0 Years to No maximum

Healthy volunteers

Inclusion criteria

* All patients (adults and children, irrespective of age) managed for suspected or surgically confirmed necrotizing soft-tissue infections (NSTI) • Consent to participate in the study

Exclusion criteria

* Patient or legal representative's refusal to participate in the study

Design outcomes

Primary

Measure	Time frame	Description
mortality	90 days	If the patient is still hospitalized, an on-site visit will be conducted; otherwise, the patient or their relative will be contacted by telephone by an investigator or a study coordinator

Secondary

Measure	Time frame	Description
hospital mortality	at hospital discharge and within 60 days of hospital admission	vital status measured at hospital discharge
time from hospital admission to first surgical debridement	within the first 72 hours of hospital admission	time period measured in hours between first hospital admission and first surgical debridement
functional outcome and quality of life	day 90 post-admission	measured using the Activity of Daily Living (ADL) and the EQ-5D-5L (EuroQol) French version scores
amputation rate	day 90	toe or limb amputation performed
annual case volume per centre	123 months	number of NSTI cases managed per year in each centre participating in the SURFAST network
bacteriological documentation	At the time of blood culture collection or operative tissue sampling	bacterial documentation of NSTIs obtained from blood cultures or cultures of operative tissue samples.

Countries

France

Contacts

CONTACTNicolas DE PROST, PU-PH

nicolas.de-prost@aphp.fr+33 1 45 17 86 37

CONTACTthomas URBINA, Dr

Tomas.urbina@aphp.fr

Outcome results